Raf-1 Kinase Is Required for Cardiac Hypertrophy and Cardiomyocyte Survival in Response to Pressure Overload

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Circulation

• Publication date

  2004-08-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1161/01.CIR.0000138190.50127.6APMID 15289381
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis.

  2003cited by this paper
• Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK

  2003cited by this paper
• Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling.

  2003cited by this paper
• Integrins Play a Critical Role in Mechanical Stress–Induced p38 MAPK Activation

  2002cited by this paper
• Activation and targeting of mitogen-activated protein kinases by G-protein-coupled receptors.

  2002cited by this paper
• Mechanical Stress‐induced DNA damage and rac‐p38MAPK Signal Pathways Mediate p53‐dependent Apoptosis in Vascular Smooth Muscle Cells

  2002cited by this paper
• Ras/Erk Signaling Is Essential for Activation of Protein Synthesis by Gq Protein-Coupled Receptor Agonists in Adult Cardiomyocytes

  2002cited by this paper
• p38 Kinase Regulates Nitric Oxide-induced Apoptosis of Articular Chondrocytes by Accumulating p53 via NFκB-dependent Transcription and Stabilization by Serine 15 Phosphorylation*

  2002cited by this paper
• Regulation of the phosphorylation of elongation factor 2 by MEK‐dependent signalling in adult rat cardiomyocytes

  2002cited by this paper
• Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gαq/Gα11 in cardiomyocytes

  2001cited by this paper
• Arterial hypertension and cardiac arrhythmias

  2001cited by this paper
• RGS4 reduces contractile dysfunction and hypertrophic gene induction in Galpha q overexpressing mice.

  2001cited by this paper
• Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade.

  2001cited by this paper
• Prognostic implications of left ventricular hypertrophy.

  2001cited by this paper
• Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes.

  2001cited by this paper
• 14‐3‐3 proteins block apoptosis and differentially regulate MAPK cascades

  2000cited by this paper
• Striated muscle-specific beta(1D)-integrin and FAK are involved in cardiac myocyte hypertrophic response pathway.

  2000cited by this paper
• Extracellular Signal-regulated Kinase Plays an Essential Role in Hypertrophic Agonists, Endothelin-1 and Phenylephrine-induced Cardiomyocyte Hypertrophy*

  2000cited by this paper
• A Role for Focal Adhesion Kinase in Phenylephrine-induced Hypertrophy of Rat Ventricular Cardiomyocytes*

  2000cited by this paper
• The MEK1–ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice

  2000cited by this paper
• Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase.

  1999cited by this paper
• RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload.

  1999cited by this paper
• Extracellular Signal-regulated Protein Kinase Activation Is Required for the Anti-hypertrophic Effect of Atrial Natriuretic Factor in Neonatal Rat Ventricular Myocytes*

  1999cited by this paper
• Ras and rho are required for galphaq-induced hypertrophic gene expression in neonatal rat cardiac myocytes.

  1998cited by this paper
• The complexity of Raf-1 regulation.

  1997cited by this paper
• Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors.

  1997cited by this paper
• Association of Tyrosine-phosphorylated c-Src with the Cytoskeleton of Hypertrophying Myocardium*

  1997cited by this paper
• The cellular and molecular response of cardiac myocytes to mechanical stress.

  1997cited by this paper
• Regulation of bFGF expression and ANG II secretion in cardiac myocytes and microvascular endothelial cells.

  1997cited by this paper
• Integrins and signal transduction pathways: the road taken.

  1995cited by this paper
• The mitogen activated protein kinase signal transduction pathway: from the cell surface to the nucleus.

  1994cited by this paper
• Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase

  1994cited by this paper
• The 3Rs of life: Ras, Raf and growth regulation.

  1994cited by this paper
• Raf-1 kinase activity is necessary and sufficient for gene expression changes but not sufficient for cellular morphology changes associated with cardiac myocyte hypertrophy.

  1994cited by this paper
• Signal transduction pathways involving the raf proto-oncogene

  1994cited by this paper
• The GRB2/Sem‐5 adaptor protein

  1994cited by this paper
• Raf-1 kinase is essential for early Xenopus development and mediates the induction of mesoderm by FGF.

  1993cited by this paper
• Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro.

  1993cited by this paper
• Raf-1 protein kinase is important for progesterone-induced Xenopus oocyte maturation and acts downstream of mos

  1993cited by this paper
• Integrins: versatility, modulation, and signaling in cell adhesion.

  1992cited by this paper
• Signal transduction by integrin receptors for extracellular matrix: cooperative processing of extracellular information.

  1992cited by this paper
• Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice.

  1991cited by this paper

• Cardiotoxic effects of BRAF/MEK inhibition: An observational study.

  2025cites this paper
• Small Interfering RNA (siRNA) for Cardiorenal Disease: Mechanistic Insights from Preclinical and Clinical Studies

  2025cites this paper
• Death receptor 5 agonists mitigate cardiac pathology in a chronic isoproterenol-induced cardiac remodeling and dysfunction.

  2025cites this paper
• Targeting PRMT1-mediated methylation of TAF15 to protect against myocardial infarction by inhibiting ferroptosis via the GPX4/NRF2 pathway

  2025cites this paper
• Dihydrocapsaicin attenuates oxidative stress and apoptosis in acute myocardial infarction via promoting Raf-1/ASK1 complex formation.

  2025cites this paper
• Identifying plasma proteomic signatures from health to heart failure, across the ejection fraction spectrum

  2024cites this paper
• Deubiquitinase USP47 Ameliorates Cardiac Hypertrophy Through Reducing Protein O-GlcNAcylation

  2024cites this paper
• Exploring TTN variants as genetic insights into cardiomyopathy pathogenesis and potential emerging clues to molecular mechanisms in cardiomyopathies

  2024cites this paper
• RAF1 facilitates KIT signaling and serves as a potential treatment target for gastrointestinal stromal tumor

  2024cites this paper
• Inhibiting the Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Cascade in Cancer and the Heart: for Better or Worse, in Sickness and Health?

  2024cites this paper
• Unveiling the Mechanism of Protective Effects of Tanshinone as a New Fighter Against Cardiovascular Diseases: A Systematic Review

  2024cites this paper
• Small molecule inhibition for RASopathy-associated hypertrophic cardiomyopathy: Clinical application of a basic concept.

  2024cites this paper
• Novel insights into cardiovascular toxicity of cancer targeted and immune therapies: Beyond ischemia with non-obstructive coronary arteries (INOCA)

  2024cites this paper
• Decoding of miR-7-5p in Colony Forming Unit–Hill Colonies as a Biomarker of Subclinical Cardiovascular Disease—A MERIT Study

  2023cites this paper
• FGF23 and klotho at the intersection of kidney and cardiovascular disease

  2023cites this paper
• Inhibiting O-GlcNAcylation impacts p38 and Erk1/2 signaling and perturbs cardiomyocyte hypertrophy

  2023cites this paper
• Recent Perspectives on Cardiovascular Toxicity Associated with Colorectal Cancer Drug Therapy

  2023cites this paper
• Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors

  2022cites this paper
• The RAF Kinase Inhibitor Protein (RKIP): Good as Tumour Suppressor, Bad for the Heart

  2022cites this paper
• An Assessment of the Therapeutic Landscape for the Treatment of Heart Disease in the RASopathies

  2022cites this paper
• Inside the Noonan “universe”: Literature review on growth, GH/IGF axis and rhGH treatment: Facts and concerns

  2022cites this paper
• The Role of PKC-MAPK Signalling Pathways in the Development of Hyperglycemia-Induced Cardiovascular Complications

  2022cites this paper
• ERK1/2: An Integrator of Signals That Alters Cardiac Homeostasis and Growth

  2021cites this paper
• Molecules linked to Ras signaling as therapeutic targets in cardiac pathologies

  2021cites this paper
• Aliskiren and L-carnitine attenuate isoproterenol-induced cardiac hypertrophy via targeting IL-6/JAK2/STAT3/SOCS3 signaling pathway

  2021cites this paper
• Cardiotoxic effects of angiogenesis inhibitors

  2021cites this paper
• Schisandrin Protects against Norepinephrine-Induced Myocardial Hypertrophic Injury by Inhibiting the JAK2/STAT3 Signaling Pathway

  2021cites this paper
• Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity Against VEGFR2, p38α, and B-Raf.

  2021cites this paper
• Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo

  2021cites this paper
• Mechanismen der Kardiotoxizität onkologischer Therapien

  2021cites this paper
• The anti-cancer drug dabrafenib is not cardiotoxic and inhibits cardiac remodelling and fibrosis in a murine model of hypertension.

  2021cites this paper
• MEK1/2 Inhibition in Murine Heart and Aorta After Oral Administration of Refametinib Supplemented Drinking Water

  2020cites this paper
• Inhibition of the NFATc4/ERK/AKT Pathway and Improvement of Thiol-Specific Oxidative Stress by Dronedarone Possibly Secondary to the Reduction of Blood Pressure in an Animal Model of Ventricular Hypertrophy

  2020cites this paper
• Role of extracellular signal-regulated kinase 1/2 signaling underlying cardiac hypertrophy

  2020cites this paper
• CD47 antibody suppresses isoproterenol-induced cardiac hypertrophy through activation of autophagy.

  2020cites this paper
• [Mechanisms of cardiotoxicity of oncological therapies].

  2020cites this paper
• Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects

  2020cites this paper
• Mechanismen der Kardiotoxizität onkologischer Therapien

  2020cites this paper
• Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib

  2020cites this paper
• Exploration of the effect of salvianolate on myocardial infarction in rats based on tandem mass tags.

  2020cites this paper
• ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy

  2019cites this paper
• Molecular mediators, characterization of signaling pathways with descriptions of cellular distinctions in pathophysiology of cardiac hypertrophy and molecular changes underlying a transition to heart failure

  2019cites this paper
• CD47 Deficiency Attenuates Isoproterenol-Induced Cardiac Remodeling in Mice

  2019cites this paper
• Structural and Functional Changes in the Na+/H+ Exchanger Isoform 1, Induced by Erk1/2 Phosphorylation

  2019cites this paper
• Cardio-Oncology: mechanisms of cardiovascular toxicity

  2018cites this paper
• Novel factors regulating cardiac remodeling in experimental models of cardiac hypertrophy and failure

  2018cites this paper
• 4,6-Diaminopyrimidines as Highly Preferred Troponin I-Interacting Kinase (TNNI3K) Inhibitors.

  2018cites this paper
• Raf kinase inhibitor protein mediates myocardial fibrosis under conditions of enhanced myocardial oxidative stress

  2018cites this paper
• Targeting the Hippo signalling pathway to enhance the protective effect of iPS cell derived cardiomyocytes

  2017cites this paper
• Sorafenib-Associated Heart Failure Complicated by Cardiogenic Shock after Treatment of Advanced Stage Hepatocellular Carcinoma: A Clinical Case Discussion

  2017cites this paper
• Raf kinase inhibitor protein: lessons of a better way for β‐adrenergic receptor activation in the heart

  2017cites this paper
• H-Ras Isoform Mediates Protection Against Pressure Overload–Induced Cardiac Dysfunction in Part Through Activation of AKT

  2017cites this paper
• The role of the transcriptional coactivator CRTC1 in the development of cardiac hypertrophy in mice

  2017cites this paper
• Cellular interplay via cytokine hierarchy causes pathological cardiac hypertrophy in RAF1-mutant Noonan syndrome

  2017cites this paper
• Effects of Novel Anticancer Therapies on Cardiac Calcium Homeostasis

  2017cites this paper
• The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities

  2016cites this paper
• Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway

  2016cites this paper
• Signaling Pathways in Cardiac Myocyte Apoptosis

  2016cites this paper
• Ubiquitin-Specific Protease 4 Is an Endogenous Negative Regulator of Pathological Cardiac Hypertrophy

  2016cites this paper
• Pivotal Role of Regulator of G-protein Signaling 12 in Pathological Cardiac Hypertrophy

  2016cites this paper
• Cardiac Specific Overexpression of hHole Attenuates Isoproterenol-Induced Hypertrophic Remodeling through Inhibition of Extracellular Signal-Regulated Kinases (ERKs) Signalling.

  2016cites this paper
• Regulator of G protein signalling 14 attenuates cardiac remodelling through the MEK–ERK1/2 signalling pathway

  2016cites this paper
• Regulation of cardiac hypertrophy and remodeling through the dual-specificity MAPK phosphatases (DUSPs).

  2016cites this paper
• IL‐6 Activates PI3K and PKCζ Signaling and Determines Cardiac Differentiation in Rat Embryonic H9c2 Cells

  2016cites this paper
• Analyzing ERK 1/2 signalling and targets.

  2016cites this paper
• Autonomous and Non-autonomous Defects Underlie Hypertrophic Cardiomyopathy in BRAF-Mutant hiPSC-Derived Cardiomyocytes

  2016cites this paper
• GSK114: A selective inhibitor for elucidating the biological role of TNNI3K.

  2016cites this paper
• Identi fi cation of Purines and 7 ‐ Deazapurines as Potent and Selective Type I Inhibitors of Troponin I ‐ Interacting Kinase ( TNNI 3 K )

  2015cites this paper
• Cardiac-Specific PID1 Overexpression Enhances Pressure Overload-Induced Cardiac Hypertrophy in Mice

  2015cites this paper
• Phosphorylating Titin's Cardiac N2B Element by ERK2 or CaMKIIδ Lowers the Single Molecule and Cardiac Muscle Force.

  2015cites this paper
• Buthionine sulfoximine, an inhibitor of glutathione biosynthesis, induces expression of soluble epoxide hydrolase and markers of cellular hypertrophy in a rat cardiomyoblast cell line: roles of the NF-κB and MAPK signaling pathways.

  2015cites this paper
• Role of transcription factor MITF and SWI/SNF chromatin remodeling enzymes subunit BRG1 in the regulation of pathological cardiac hypertrophy

  2015cites this paper
• The role of p21-activated kinase 1 (Pak1) in the heart

  2015cites this paper
• Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction.

  2015cites this paper
• Cardiac Side Effects Associated with Kinase Proteins and Their Signaling Pathways

  2015cites this paper
• Cardiac Gab1 deletion leads to dilated cardiomyopathy associated with mitochondrial damage and cardiomyocyte apoptosis

  2015cites this paper
• Dominant negative Ras attenuates pathological ventricular remodeling in pressure overload cardiac hypertrophy.

  2015cites this paper
• Loss of proteostasis as a substrate for atrial fibrillation

  2014cites this paper
• The Mammalian Ste 20-like Kinase 2 ( Mst 2 ) Modulates Stress-induced Cardiac Hypertrophy *

  2014cites this paper
• Overexpression of Mitofilin in the Mouse Heart Promotes Cardiac Hypertrophy in Response to Hypertrophic Stimuli

  2014cites this paper
• Cancer Therapy–Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies

  2014cites this paper
• B-RAF and its novel negative regulator reticulocalbin 1 (RCN1) modulates cardiomyocyte hypertrophy.

  2014cites this paper
• Depolarization of Cellular Resting Membrane Potential Promotes Neonatal Cardiomyocyte Proliferation In Vitro

  2014cites this paper
• Elucidating ERK2 function in the heart.

  2014cites this paper
• Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives.

  2014cites this paper
• Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway

  2014influential citation
• Depolarization of Cellular Resting Membrane Potential Promotes Neonatal Cardiomyocyte Proliferation In Vitro

  2014cites this paper
• Low Intensity Pulsed Ultrasound (LIPUS) Influences the Multilineage Differentiation of Mesenchymal Stem and Progenitor Cell Lines through ROCK-Cot/Tpl2-MEK-ERK Signaling Pathway*

  2014cites this paper
• The Mammalian Ste20-like Kinase 2 (Mst2) Modulates Stress-induced Cardiac Hypertrophy*

  2014cites this paper
• The Roles of Phosphodiesterase (PDE) 3A and 3B as Regulators of Cardiac Function in Disease

  2014cites this paper
• The role of the paracrine/autocrine mediator endothelin‐1 in regulation of cardiac contractility and growth

  2013cites this paper
• Themed section: endothelin

  2013cites this paper
• The Ral Exchange Factor Rgl2 Promotes Cardiomyocyte Survival and Inhibits Cardiac Fibrosis

  2013cites this paper
• Interference with ERKThr188 phosphorylation impairs pathological but not physiological cardiac hypertrophy

  2013cites this paper
• Key role of ERK1/2 molecular scaffolds in heart pathology

  2013cites this paper
• Reducing Oxidative Stress and Manipulating Molecular Signaling Events Using Resveratrol as a Therapy for Pathological Cardiac Hypertrophy

  2013cites this paper
• Small G proteins in the cardiovascular system: physiological and pathological aspects.

  2013cites this paper
• The role of Extracellular-Regulated Protein Kinase 2 (ERK2) in cardiac hypertrophic remodelling

  2013cites this paper
• A Cardiac-enriched MicroRNA, miR-378, Blocks Cardiac Hypertrophy by Targeting Ras Signaling*

  2013cites this paper
• Investigating the homologue of the mammalian gene myocyte stress 1 in Drosophila melanogaster

  2013cites this paper